MX9302021A - Composicion y substrato cromogenico para diagnosticar la enfermedad de alzheimer. - Google Patents
Composicion y substrato cromogenico para diagnosticar la enfermedad de alzheimer.Info
- Publication number
- MX9302021A MX9302021A MX9302021A MX9302021A MX9302021A MX 9302021 A MX9302021 A MX 9302021A MX 9302021 A MX9302021 A MX 9302021A MX 9302021 A MX9302021 A MX 9302021A MX 9302021 A MX9302021 A MX 9302021A
- Authority
- MX
- Mexico
- Prior art keywords
- substrate
- disease
- diagnosing alzheimer
- chromogenic composition
- patient
- Prior art date
Links
- 239000000758 substrate Substances 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86516792A | 1992-04-09 | 1992-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9302021A true MX9302021A (es) | 1994-08-31 |
Family
ID=25344883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9302021A MX9302021A (es) | 1992-04-09 | 1993-04-07 | Composicion y substrato cromogenico para diagnosticar la enfermedad de alzheimer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5981208A (en, 2012) |
| EP (1) | EP0564946A1 (en, 2012) |
| JP (1) | JP3510902B2 (en, 2012) |
| KR (1) | KR100282031B1 (en, 2012) |
| AU (1) | AU672379B2 (en, 2012) |
| CA (1) | CA2086165A1 (en, 2012) |
| IL (1) | IL105216A (en, 2012) |
| MX (1) | MX9302021A (en, 2012) |
| NZ (1) | NZ247356A (en, 2012) |
| TW (1) | TW253941B (en, 2012) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
| AU679675B2 (en) * | 1992-05-11 | 1997-07-10 | Bayer Corporation | Methods for detecting beta amyloid precursor protein processing enzymes |
| EP0694076A1 (en) * | 1992-12-16 | 1996-01-31 | Bayer Corporation | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
| WO1995026505A1 (en) * | 1994-03-29 | 1995-10-05 | Gruppo Lepetit S.P.A. | Solid phase immunoassay to detect inhibitors of proteolytic enzymes |
| US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| US6781029B2 (en) | 2000-07-13 | 2004-08-24 | University Of South Florida | Transgenic animal and methods |
| AU2001277217A1 (en) * | 2000-07-28 | 2002-02-13 | Blood Center Research Foundation | Synthetic and recombinant substrates for the detection of the von willebrand factor-cleaving protease |
| AU2001278084A1 (en) * | 2000-07-31 | 2002-02-13 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
| FR2816411B1 (fr) * | 2000-11-03 | 2003-07-04 | Inst Nat Sante Rech Med | Moyens de detection de la transformation pathologique de la proteine app et leurs applications |
| US6649346B2 (en) * | 2001-03-30 | 2003-11-18 | Board Of Regents, The University Of Texas | Methods of identifying agents that affect cleavage of amyloid-β precursor protein |
| DE10230838B4 (de) * | 2002-07-04 | 2005-02-03 | Mediquant Gmbh | Diagnostische Verwendung von pharmazeutischen Substanzen |
| US7682795B2 (en) * | 2002-07-30 | 2010-03-23 | The J. David Gladstone Institutes | Method of diagnosing Alzheimer's Disease |
| AU2003262937B2 (en) * | 2002-08-27 | 2009-05-07 | Bristol-Myers Squibb Company | Adzymes and uses thereof |
| WO2007119685A1 (ja) * | 2006-04-13 | 2007-10-25 | Sanko Junyaku Co., Ltd. | β－アミロイドの血中分解速度測定によるアルツハイマー病の検定方法及び診断試薬 |
| WO2008027017A1 (en) * | 2006-08-31 | 2008-03-06 | Singapore Health Services Pte Ltd | Modulation of neural activity and/or condition |
| KR20090094854A (ko) * | 2006-12-22 | 2009-09-08 | 제넨테크, 인크. | Ａｐｐ에 대한 ｄｒ６의 결합을 억제하는 ｄｒ６ 항체, 및 신경학적 질환의 치료에 있어서의 그의 용도 |
| CN102124336A (zh) * | 2008-06-12 | 2011-07-13 | 健泰科生物技术公司 | 用于筛选抑制神经变性的化合物的方法 |
| EP2342563A1 (en) * | 2008-10-20 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta |
| AU2009319864A1 (en) | 2008-11-25 | 2011-07-14 | Biogen Idec Ma Inc. | Use of DR6 and P75 antagonists to promote survival of cells of the nervous system |
| TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
| US20110110942A1 (en) * | 2009-11-12 | 2011-05-12 | Genentech, Inc. | Method of promoting dendritic spine density |
| KR101352670B1 (ko) | 2010-06-15 | 2014-01-17 | 울산대학교 산학협력단 | 알츠하이머 전구단백질 분비 펩타이드의 축적물을 포함하는 뇌 노화 감별 진단 마커 |
| US20120181450A1 (en) * | 2011-01-18 | 2012-07-19 | Electronics And Telecommunications Research Institute | Method and apparatus for detecting bio material using photoelectric conversion device, and method for manufacturing photoelectric conversion device |
| WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
| JP2013158281A (ja) * | 2012-02-03 | 2013-08-19 | Shionogi & Co Ltd | 新規ｂａｃｅ１活性測定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223482A (en) * | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
| US4874694A (en) * | 1987-04-07 | 1989-10-17 | The Rockefeller University | Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
| US5039511A (en) * | 1987-04-08 | 1991-08-13 | Salutar, Inc. | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
| US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
| WO1991013904A1 (en) * | 1990-03-05 | 1991-09-19 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
| US5595883A (en) * | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
| AU8215391A (en) * | 1990-06-29 | 1992-01-23 | Case Western Reserve University | Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor |
| US5200339A (en) * | 1990-08-17 | 1993-04-06 | Abraham Carmela R | Proteases causing abnormal degradation of amyloid β-protein precursor |
| AU643835B2 (en) * | 1990-08-17 | 1993-11-25 | Boston University | Proteases causing abnormal degradation of amyloid beta-protein precursor |
| US5200324A (en) * | 1990-09-04 | 1993-04-06 | E. R. Squibb & Sons, Inc. | Method of diagnosing senile dementia of the Alzheimer type |
| US5686269A (en) * | 1994-07-28 | 1997-11-11 | The Mclean Hospital Corporation | Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid |
-
1992
- 1992-12-23 CA CA002086165A patent/CA2086165A1/en not_active Abandoned
-
1993
- 1993-02-19 AU AU33187/93A patent/AU672379B2/en not_active Ceased
- 1993-03-29 EP EP93105149A patent/EP0564946A1/en not_active Withdrawn
- 1993-03-30 IL IL10521693A patent/IL105216A/en not_active IP Right Cessation
- 1993-03-31 KR KR1019930005267A patent/KR100282031B1/ko not_active Expired - Fee Related
- 1993-04-07 MX MX9302021A patent/MX9302021A/es unknown
- 1993-04-07 TW TW082102556A patent/TW253941B/zh active
- 1993-04-07 NZ NZ247356A patent/NZ247356A/en unknown
- 1993-04-08 JP JP10497093A patent/JP3510902B2/ja not_active Expired - Fee Related
-
1994
- 1994-10-06 US US08/319,339 patent/US5981208A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NZ247356A (en) | 1995-04-27 |
| KR100282031B1 (ko) | 2001-06-01 |
| EP0564946A1 (en) | 1993-10-13 |
| TW253941B (en, 2012) | 1995-08-11 |
| CA2086165A1 (en) | 1993-10-10 |
| AU3318793A (en) | 1993-10-14 |
| JP3510902B2 (ja) | 2004-03-29 |
| KR930022086A (ko) | 1993-11-23 |
| IL105216A0 (en) | 1993-07-08 |
| US5981208A (en) | 1999-11-09 |
| IL105216A (en) | 1996-10-16 |
| JPH0751096A (ja) | 1995-02-28 |
| AU672379B2 (en) | 1996-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9302021A (es) | Composicion y substrato cromogenico para diagnosticar la enfermedad de alzheimer. | |
| DK47588A (da) | Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose | |
| SE9103332D0 (sv) | Method for the diagnosis of blood coagulation desorders | |
| ATE161055T1 (de) | Polymorphie des glykoproteins iiia der menschlichen blutplättchenmembran und diagnostische applikation davon | |
| ATE100209T1 (de) | Antikoerper verwendende diagnostische methoden. | |
| ES2151880T3 (es) | Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones. | |
| DE69937368D1 (de) | Nachweis von erkrankungen der nieren und behandlung | |
| DE69941429D1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
| DE3687741D1 (de) | Geraet zur ultraschallechographie der bewegung von koerperorganen, insbesondere der blutstroemung oder des herzens. | |
| ATE293460T1 (de) | Peptidvektoren von stoffen die durch die blut- hirn-scranke dringen | |
| DE69309906D1 (de) | Behandlung für entzündungserkrankung des darmes | |
| KR890011606A (ko) | 항응고제 | |
| DE69031656D1 (de) | Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung | |
| NO920125D0 (no) | Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve | |
| DE69519338D1 (de) | Herstellung von Alpha-1-antichymotrypsin | |
| FI922666A0 (fi) | Diagnostiskt foerfarande. | |
| DE50105971D1 (de) | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 | |
| FR2849205B1 (fr) | Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification | |
| ES516672A0 (es) | "procedimiento para preparar un agente para la determinacion del cofactor de ristocetina". | |
| RU96110597A (ru) | Способ диагностики заболеваний пародонта | |
| FI844645A0 (fi) | 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar. | |
| ATE223056T1 (de) | Diagnose von neuro-degenerativen erkrankungen | |
| ATE407216T1 (de) | Testsystem zur bestimmung von in-vivo aktiven proteasen der hämostase in biologischen flüssigkeiten | |
| ES2163921T3 (es) | Substancia con actividad renina que contiene prorrenina humana y los anticuerpos contra el profragmento de prorrenina. | |
| IT1215408B (it) | Dispositivo per l'adduzione dosata di lega leggera liquida nel cilindro di pressione. |